Femasys Inc. (FEMY)
NASDAQ: FEMY
· Real-Time Price · USD
1.14
-0.04 (-3.39%)
At close: May 06, 2025, 3:59 PM
1.13
-0.88%
After-hours: May 06, 2025, 07:54 PM EDT
-3.39% (1D)
| Bid | 1.11 |
| Market Cap | 30.95M |
| Revenue (ttm) | 1.63M |
| Net Income (ttm) | -18.82M |
| EPS (ttm) | -0.85 |
| PE Ratio (ttm) | -1.34 |
| Forward PE | -2.43 |
| Analyst | Buy |
| Ask | 1.15 |
| Volume | 490,640 |
| Avg. Volume (20D) | 439,793 |
| Open | 1.18 |
| Previous Close | 1.18 |
| Day's Range | 1.12 - 1.22 |
| 52-Week Range | 0.86 - 1.80 |
| Beta | -2.52 |
About FEMY
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United Sta...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date Jun 18, 2021
Employees 69
Stock Exchange NASDAQ
Ticker Symbol FEMY
Website https://www.femasys.com
Analyst Forecast
According to 2 analyst ratings, the average rating for FEMY stock is "Buy." The 12-month stock price forecast is $11.5, which is an increase of 908.77% from the latest price.
Stock ForecastsNext Earnings Release
Femasys Inc. is scheduled to release its earnings on May 20, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-11.84%
Femasys shares are trading lower after the company...
Unlock content with
Pro Subscription
7 months ago
+7.48%
Femasys shares are trading higher after the company announced distribution partnerships for the commercialization of FemaSeed for over $1.3 million in the Spanish market.
